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Abstract
Background: We examined the methodological quality of guidelines on syndromes conferring genetic
susceptibility to breast cancer.
Methods: PubMed, EMBASE, and Google were searched for guidelines published up to October 2010. All
guidelines in English were included. The Appraisal of Guidelines, Research and Evaluation (AGREE) instrument was
used to assess the quality of the guidelines, and their reported evidence base was evaluated.
Results: Thirteen guidelines were deemed eligible: seven had been developed by independent associations, and
the other six had national/state endorsements. Four guidelines performed satisfactorily, achieving a score of greater
than 50% in all six AGREE domains. Mean ± SD standardized scores for the six AGREE domains were: 90 ± 9% for
‘scope and purpose’, 51 ± 18% for ‘stakeholder involvement’, 55 ± 27% for ‘rigour of development’, 80 ± 11% for
‘clarity and presentation’, 37 ± 32% for ‘applicability’, and 47 ± 38% for ‘editorial independence’. Ten of the thirteen
guidelines were found to be based on research evidence.
Conclusions: Given the ethical implications and the high costs of genetic testing for hereditary breast cancer,
guidelines on this topic should provide clear and evidence-based recommendations. Our analysis shows that there
is scope for improving many aspects of the methodological quality of current guidelines. The AGREE instrument is
a useful tool, and could be used profitably by guidelines developers to improve the quality of recommendations.
Keywords: Breast cancer, BRCA1/2, Familial breast/ovarian cancer, Cancer screening, Cancer surveillance
Background
Breast cancer comprises 22.9% of all cancers in women,
and an estimated 460,000 deaths from breast cancer
occurred worldwide in 2008, representing around 14% of
cancer deaths in women. Breast cancer represents a chal-
lenge for public health, and in spite of the extremely high
incidence rates, secondary prevention is considered to
have a major role in decreasing mortality rates and costs.
However, this notion has been challenged by a recent
Cochrane review [1], reporting that screening reduces
breast-cancer mortality by around 15%, which corresponds
to an absolute risk reduction of only 0.05%. Nevertheless,
regardless of the real effect of screening on the mortality
related to sporadic breast cancer, the current scientific evi-
dence supports secondary prevention for individuals at a
high genetic risk of developing breast cancer [2].
A considerable proportion of breast cancers presents
with genetic recurrence patterns. The two genes most fre-
quently involved in hereditary breast cancer are the tumor
suppressor genes BRCA1 and BRCA2, which are mutated
in approximately 25% of hereditary breast cancers and
around 5% of all breast cancers. Woman carrying muta-
tions in either BRCA1 or BRCA2 have an 80 to 90% life-
time risk of developing breast cancer and a 20 to 50%
chance of developing ovarian cancer [3]. Thanks to early
multimodal screening, breast cancer in people carrying
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BRCA1 or BRCA2 mutations can be diagnosed at an early
stage, with consequent favorable effects on their survival
and quality of life, and also on costs for the health system
[2]. Additionally, carriers can benefit from specific tertiary
prevention interventions, as the risk of ovarian, contralat-
eral breast cancer, and of other associated carcinomas
(such as prostate, pancreas, and colon) is considerable [3].
It is therefore clear that the identification of mutation car-
riers of BRCA1/2 represents a key issue in public health
for the potential implementation of specific prevention
and management programs, such as intensive risk-
adjusted screening, counseling, and prophylactic treat-
ments [2,3].
The probability that an individual is carrier of a BRCA1
or BRCA2 mutation can be estimated based on the fre-
quency and age of onset of the disease in relatives and on
the organs affected (breast, ovary). Several algorithms are
available to estimate the risk of being a carrier of the
mutations [2,3]. However, genetic testing, however, is the
ultimate tool for diagnosis; issues concerning who should
be tested and in which context, and the management of
test users, are not easily dealt with, and the tests are
expensive, and require a great deal of human resources
and expertise. There are also ethical and legal issues that
need to be considered; genetic information is sensitive,
and data protection is necessary. All these issues need to
be clearly addressed by valid, reliable, independent, and
easily applicable guidelines. The Appraisal of Guidelines,
Research, and Evaluation (AGREE) instrument represents
a tool for a thorough quality assessment of guidelines [4].
AGREE is a validated tool produced by the PL96-3669
research program funded by the European Union. It has
been developed by researchers and policy-makers from
several European countries, as well as Canada, the USA,
and New Zealand [4]. Over the past few years, AGREE has
become a benchmark in both the evaluation of existing
guidelines [5-7] and the development of new ones [8,9].
Application of AGREE has shown that the quality of clini-
cal and preventive guidelines is generally poor [10,11], and
that some aspects of their quality, such as their applicabil-
ity and the involvement of stakeholders, are particularly
unsatisfactory [11-13]. The instrument has been applied to
guidelines produced in virtually every field of clinical prac-
tice, focusing on therapies, treatments, and procedures,
and was also recently applied to genetic guidelines on col-
orectal cancer [11].
The aim of this study was to provide a critical evalua-
tion, using the AGREE instrument, of the quality of guide-
lines focusing on the management of individuals at higher
genetic risk of breast cancer.
Methods
We searched for guidelines published up to October 2010
that aimed to provide recommendations on the genetic
screening, surveillance, and management of people who
have or are suspected to have a hereditary breast-cancer
susceptibility syndrome. The MedLine, EMBASE and
Google databases were searched through using the fol-
lowing terms: (Guidelines OR Recommendations) AND
Breast AND Cancer AND Screening AND (BRCA$ OR
Hereditary). Reference lists of the eligible papers were
also searched manually. We included only guidelines
published in English that provided explicit recommenda-
tions on the management of individuals who had or were
at risk of having genetic forms of breast cancer. When
more than one set of guidelines was produced by the
same professional body, only the most recently issued
was considered. All guidelines on breast-cancer screening
reporting non-original (that is, referring to other sets of
guidelines on the matter of hereditary forms of breast
cancer) recommendations were excluded. For each guide-
line, we specified the target population and objectives. In
particular, the target population was defined as the gen-
eral population or specific subgroups. Recommendations
on breast cancer in men were also reported.
Objectives were grouped as follows.
• Assessment of level of risk for breast cancer (low,
average, high) of the target population.
• Definition of the criteria of appropriateness for
genetic testing.
• Definition of the criteria for empirical diagnosis of
susceptibility syndromes.
• Assessment of surveillance options for individuals
with a diagnosis or suspicion of susceptibility syndromes.
• Evaluation of options for prophylactic or post-
diagnosis treatments.
Three investigators (BS, EDF, NN) appraised all the
selected guidelines using the AGREE instrument [4].
AGREE provides criteria to assess the quality of the
methods used for developing the guidelines and of their
reporting. The instrument consists of 23 key items orga-
nized into 6 domains: ‘scope and purpose’, ‘stakeholder
involvement’, ‘rigour of development’, ‘clarity and presen-
tation’, ‘applicability’ and ‘editorial independence’. Each
domain is intended to capture a separate dimension of
guideline quality. Items were evaluated independently by
the three investigators using a four-point scale as indi-
cated by the AGREE instructions (from 4 (strongly agree)
down to 1 (strongly disagree)). The summary score of
each domain is calculated by summing the scores of all
of the individual items present in the domain, and suc-
cessively by standardizing the total score as a percentage
of the maximum possible score for that domain, as sug-
gested by the authors of AGREE (range 0 to 100%). Item
scores were discussed by the three appraisers, and large
scoring discrepancies (defined as ≤2 points difference in
the score assigned by the evaluators to the same item)
were resolved by consensus.
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According to the AGREE collaboration Group, based
on the results for each of the six domains evaluated, a
guideline can be ‘strongly recommended’, ‘recommended
with provisions’, or ‘not recommended’. The instrument
does not provide criteria to formulate the overall assess-
ment on the guideline, leaving it up to the discretion of
the evaluator. We considered as satisfactory any guideline
that scored at least 50% in all six of the domains as
defined by AGREE. Guidelines were further classified
based on whether they were developed by independent
associations or by national/state-endorsed societies. The
Mann-Whitney test was used to compare the median
values of each of the 6 domain scores obtained by apply-
ing the AGREE instrument to the 17 guidelines, based on
the presence or absence of an endorsement.
We also integrated the AGREE instrument by applying
an additional system aimed at evaluating whether guide-
lines could be considered evidence-based. Following a
scheme already proposed in the literature [11,14], we
defined three criteria for this purpose: the search strategy
having been reported in at least one database, the quality




The electronic databases search identified 215 results
from MedLine, 188 from EMBASE, and over 302,000
from Google. After a first reading of the titles, any results
that were not guidelines were excluded. Duplicates were
also excluded, and the application of the inclusion and
exclusion criteria (Figure 1) led to the final selection of
13 sets of guidelines (detailed in Table 1) [2,15-27]. All
the selected guidelines were developed in English-speak-
ing countries because of the restrictions used in the
research (eight from the USA [2,16,17,19-21,25,27], two
from the UK [23,24,26], and one each from Canada [22],
New Zealand [18] and Singapore [15]). Of the 13 guide-
lines, 7 were produced by independent professional
scientific societies [2,16,17,19-21,27], whereas six were
developed with the endorsement of national/state autho-
rities [15,18,22-26] (Table 1).
Target population and objectives of guidelines
The guidelines analyzed are relatively homogeneous in
terms of target populations: they all begin by focusing on
the general population and then provide specific recom-
mendations on patients with high-risk syndromes.
Regarding the objectives, surveillance recommendations
are provided by all the guidelines, but not all give indica-
tions about how to perform a risk assessment [15,17,21],
criteria of appropriateness for genetic testing [15,21], the
definition of empirical diagnostic criteria of susceptibility
syndromes [15,19,21] or the available treatment options
[25]. Apart from the BRCA1/2 syndromes, most guide-
lines also provide recommendations on, or at least
mention, less common syndromes such as Li-Fraumeni,
Peutz-Jeghers, and Cowden syndromes (Table 1).
Although the main recommendations are focused on
women, all the guidelines provide at least some recom-
mendations on syndromic breast cancer in men.
Appraisal of guidelines
Based on the criteria defined in the methods section,
10 (77%) of the 13 guidelines are evidence-based
[2,15,17-19,22-27] (table 1), and apart from the 3 excep-
tions [16,20,21], all guidelines stated, either in the text
or in a clearly specified link, the methods used in the lit-
erature search, the quality of the evidence, and the
strength of recommendations reported.
Application of the AGREE instrument produced six
standardized scores for each guideline, pertaining to the
specific domain (Table 2). We deemed satisfactory the
guidelines produced by the Institute for Clinical Systems
Improvement (ICSI)[17], The New Zealand Guidelines
Group (NZGG) [18], the UK National Health System
(NHS) [23,24] and the Scottish Intercollegiate Guidelines
Network (SIGN) [26], which all had a score of at least
50% in each of the six domains. All the other guidelines
scored below 50% in at least one domain. The lowest
scores were assigned to the Guidelines produced by the
Ministry of Health of Singapore [15], with five of the six
domains scoring below 50%. Two more guidelines
[16,22] also achieved scores of below 50% in four of the
six domains (Table 2).
As shown in Table 2, the highest score (100%) for
domain 1 (scope and purpose) was given to the guide-
lines of the American College of Obstetricians and
Gynecologists (ACOG) [16] and the National Society of
Genetic Counselors [20], whereas the lowest score (7%)
was assigned to the Singapore guideline [15]. Scores for
domain 2 (stakeholder involvement) were generally very
low, ranging from 75% (NZGG [18] and NHS [23,24]) to
8% (University of Michigan [21]). The SIGN guidelines
[26] gained the highest score (97%) for domain 3 (rigour
of development), whereas the lowest (8%) was assigned to
the guidelines from Towards Optimized Practice Alberta
[22]. The highest score (100%) assigned to domain 4
(clarity and presentation) was achieved by the NZGG
[18], and the lowest (56%) by the American Cancer
Society [27]. SIGN [26] had the best score (89%) in
domain 5 (applicability), whereas the University of Michi-
gan had the worst (0%) [21]. Finally, the top scores
(100%) for domain 6 (editorial independence) were
obtained by the National Cancer Comprehensive Net-
work [2] and the NZGG [17], whereas four guidelines
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[15,16,19,22] scored 0% in this domain for not being
explicit on conflicts of interest and on independence
statements from funding bodies.
Table 3 details the overall mean scores for all the 23
items included in the 6 domains, and the overall mean
standardized scores for each of the 6 domains from the 13
guidelines evaluated. The highest score was obtained for
domain 1 (scope and purpose) with a value of 90 ± 9%,
and domain 4 (clarity and presentation) with 80 ± 11%,
whereas the lowest scores were for domain 5 (applicability)
with 37 ± 32%, and domain 6 (editorial independence)
with 47 ± 38%. Domains 2 (stakeholder involvement) and
3 (rigour of development) scored overall 51 ± 18% and
55 ± 27%, respectively (Table 3).
Comparison between endorsed and non-endorsed
guidelines showed that the former performed better in
five of the six domains, although no statistical signifi-
cance was attained for any domain.
Discussion
Genetic forms of breast cancer are an issue for public
health. Women with a family history of breast cancer,
and especially women with genetically known forms of
susceptibility, can benefit from appropriate prevention
and treatment interventions. Outcomes for breast cancer
are strongly associated with the stage and degree of dis-
ease progression at the time of diagnosis, and this also
holds true for genetically determined forms. Because
effective screening surveillance and adequate preventive
measures are proven to have a dramatic effect on the sur-
vival and the quality of life of individuals with inherited
breast-cancer syndromes [1,3], specific recommendations
to define high-risk individuals and appropriate screening
protocols should be provided. It is essential that, given
the ethical implications of genetic testing, and also in
consideration of the high costs related to their adminis-
tration, guidelines should provide very clear and
Figure 1 Flowchart of the guidelines selection process.
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evidence-based recommendations on who should be
tested, based on their personal and family history and on
clinical criteria.
In this study, we aim to evaluate the quality of metho-
dology of guidelines dealing with the issue of genetic
testing for hereditary breast cancer, using the AGREE
instrument. The application of AGREE allows evaluation
of various aspects of guidelines quality: ‘scope and pur-
pose’, taking into account whether the objectives, the
clinical questions, and the target population are properly
specified; ‘stakeholder involvement’, assessing which pro-
fessional groups have been involved in the guideline
development, and whether patients’ views and prefer-
ences have been sought; ‘rigour of development’, with a
list of key items focusing on the methods used by the
developers, starting from the literature search up to the
external review of the recommendations; ‘clarity and pre-
sentation’, focusing on how easily the user is able to find
the key recommendations and the possible alternatives in
the guideline; ‘applicability’, with three key items asses-
sing how organizational barriers, potential cost implica-
tions, and patient monitoring/audit have been discussed;
and ‘editorial independence’, assessing independence
statements and records of potential conflicts of interest
of the guideline developers.
The evaluation of the quality of the evidence which the
guidelines build upon was beyond our objectives. We
focused on the methods used in the course of develop-
ment of the guidelines, which is the purpose of the
AGREE instrument, based on the rationale that high
methodological quality is fundamental in terms of cred-
ibility, reproducibility and transparency of guidelines.
Furthermore, in the case of genetic susceptibility syn-
dromes for breast cancer, as of today, there is a limited
body of evidence focusing on the best screening and
management options.
Table 1 Description of the thirteen breast cancer screening guidelines included in the study.















Breast Cancer Screening and Diagnosis (National





Yes Yes Yes Yes
Health Screening, MOH Clinical Practice Guidelines
(Ministry of Health, Singapore), 20102 [15]
Yes BRCA1/2 General
population
No No No Yes
Hereditary Breast and Ovarian Cancer Syndrome




Yes Yes Yes Yes
Diagnosis of Breast Disease (Institute for Clinical





No Yes Yes Yes
Management of Early Breast Cancer (New Zealand





Yes Yes Yes Yes
Guidelines for Breast Screening with MRI as an






Yes Yes No Yes
Risk Assessment and Genetic Counseling for
Hereditary Breast and Ovarian Cancer:






Yes Yes Yes Yes
Adult Preventive Health Care: Cancer Screening
(University of Michigan), 20071 [21]
No BRCA1/2 General
population
No No No Yes
The Early Detection of Breast Cancer (Towards
Optimized Practice Alberta), 20072 [22]
Yes BRCA1/2 General
population
Yes Yes Yes Yes
Familial breast cancer + Update (NHS), 20062 [23,24] Yes BRCA1/2, LFS General
population
Yes Yes Yes Yes
Genetic Risk Assessment and BRCA Mutation Testing
for Breast and Ovarian Cancer Susceptibility:
Recommendation Statement (U.S. Preventive
Services Task Force), 20042 [25]
Yes BRCA1/2 General
population
Yes Yes Yes No
Management of Breast Cancer in Women (Scottish
Intercollegiate Guidelines Group), 20042 [26]
Yes BRCA1/2 General
population
Yes Yes Yes Yes
Guidelines for Breast Cancer Screening (American





Yes Yes Yes Yes
Abbreviations: CS, Cowden syndrome; LFS, Li-Fraumeni syndrome
1Independent body/no endorsement.
2National/state endorsement.
3Other syndromes: Bannayan-Riley-Ruvalcaba syndrome, Peutz-Jeghers syndrome, hereditary diffuse gastric cancer and ataxia telangectasia.
Simone et al. BMC Medicine 2012, 10:143
http://www.biomedcentral.com/1741-7015/10/143
Page 5 of 9
All the guidelines considered in this review are based
on the same studies, therefore the recommendations
necessarily converge. The recommendations on the
topic given by the guidelines analyzed are as follows.
• All individuals at high risk (individuals from known
high-risk families, or with high scores on the BRCAPRO
[28] or BOADICEA [29] programs, or deemed at high
risk based on clinical judgment) should be offered refer-
ral for information on genetic testing.
• Counseling from training personnel should be always
available.
• If a mutation is identified in one individual from a
high-risk family, predictive testing should then be
offered to all adult at-risk family members.
• Known carriers of a BRCA1 or BRCA2 gene mutation
should be offered counseling and the option of prophylac-
tic mastectomy, and prophylactic salpingo-oophorectomy
should also be discussed.
• Individualized screening strategies for known carriers
of BRCA1 or BRCA2 gene mutations should be consid-
ered, such as earlier screening, shorter intervals between
screens, and possibly annual MRI surveillance.
The most important difference between guidelines,
however, and we believe it to be noteworthy, is how the
different developers used the same evidence to produce
the guidelines. The application of AGREE detected some
major flaws in the development of the 13 guidelines on
the topic, as some of the aspects investigated by AGREE
were not included in these guidelines. With very few
exceptions, the 13 guidelines all performed poorly with
regard to ‘stakeholder involvement’ (domain 2) and ‘edi-
torial independence’ (domain 6). Regarding stakeholder
involvement, target users of the guideline (general practi-
tioners, gynecologists, oncologists) remained generally
undefined (key item 6), patient representatives were
seldom involved (key item 5) in guideline development,
and most guidelines were not piloted among end users
(key item 7). Regarding editorial independence, explicit
statements of independence from funding bodies (key
item 22) were often not clearly stated, and did not allow
the identification of possible conflicts of interest. The
application of AGREE also showed that the methodologi-
cal quality of the guidelines was suboptimal in terms of
‘rigour of development’ (domain 3) and ‘applicability’
(domain 5). Most guidelines lacked explicit statements
on the criteria for selecting the evidence (key item 9), on
whether they were externally reviewed before publication
(key item 13), and on procedures for their update (key
item 14). Generally speaking, the AGREE instrument
gave high scores for domains 1 (scope and purpose) and
Table 2 Standardized scores (%) on the Appraisal of Guidelines, Research and Evaluation (AGREE) instrument assigned
















92.6 63.9 50.8 83.3 7.4 100.0
Ministry of Health, Singapore2 [15] 7.4 47.2 12.7 69.4 25.9 0.0
American College of Obstetricians
and Gynecologists1 [16]
100.0 44.4 33.3 77.8 18.5 0.0
Insitute for Clinical Systems
Improvement1 [17]
74.1 50.0 52.4 80.6 55.6 55.6
New Zealand Guidelines Group2
[18]
81.5 75.0 81.0 100.0 85.2 100.0
American Cancer Society (MRI)1 [19] 96.3 52.8 65.1 86.1 44.4 0.0
National Society of Genetic
Counselors1 [20]
100.0 41.7 69.8 72.2 44.4 50.0
University of Michigan1 [21] 92.6 8.3 39.7 80.6 0.0 88.9
Towards Optimized Practice
Alberta2 [22]
74.1 33.3 7.9 69.4 18.5 0.0
National Health System2 [23,24] 88.9 75.0 87.3 88.9 77.8 50.0
U.S. Preventive Services Task Force2
[25]
96.3 72.2 69.8 86.1 3.7 50.0
Scottish Intercollegiate Guidelines
Group2 [26]
96.3 50.0 96.8 86.1 88.9 72.2
American Cancer Society1 [27] 92.6 47.2 52.4 55.6 11.1 50.0
1Independent body/no endorsement,.
2National/state endorsement,
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4 (clarity and presentation), even though not all guide-
lines received fully positive evaluations.
Although there was a good degree of convergence
between guidelines in terms of recommendations pro-
vided, our study does have implications for clinical prac-
tice as well. As mentioned above, the AGREE instrument
provides six independent scores for six corresponding
aspects of the guidelines; clinicians would be interested
primarily in the ‘applicability’ domain. It is fundamental
that recommendations are not only rigorous in method
but also feasible when applied to a specific clinical setting.
In this sense, we recommend clinicians should rely prefer-
entially on the guidelines that performed better with
regards to the ‘applicability’ domain [18,23,24,26], as those
guidelines gave more consideration to issues related to
overcoming possible organizational barriers when applying
the recommendation (key item 19), and to presenting cri-
teria for monitoring and audit purposes (key item 20).
By applying the AGREE instrument to the 13 guidelines
on genetic testing for breast cancer, we found that guide-
lines developed by the ICSI [17], the NZGG [18], the
SIGN [26] and the NHS [23,24] scored above 50% in all
six domains, with the NZGG [18], who acknowledged the
adoption of AGREE in the guideline development, scor-
ing above 70% in all domains. As for the other guidelines,
two [2,25] yielded poor scores (below 50%) in one of the
six domains, three [19,20,27] in two of the six domains,
one [21] in three of the six domains, two [16,22] in four
of the six domains, and one [15] in five of the six
domains.
The guidelines produced by societies with an official
endorsement tended to perform better with regard to all
Table 3 Mean scores for the 23 items and overall standardized scores for each domain from the 13 guidelines
evaluated assessed with AGREE.
Domain Item Mean score
(range)
1 (Scope and purpose) • The overall objective(s) of the guideline is (are) specifically described 3.7 (2.3 to 4.0)
• The clinical question(s) covered by the guideline is(are) specifically described 3.6 (2.7 to 4.0)
• The patients to whom the guideline is meant to apply are specifically described 3.7 (3.3 to 4.0)
Overall standardized score, % 89.5 (66.7 to 100.0)
2 (Stakeholder
involvement)
• The guideline development group includes individuals from all the relevant professional groups 3.3 (1.3 to 4.0)
• The patients’ views and preferences have been sought 2.7 (1.3 to 4.0)
• The target users of the guideline are clearly defined 3.0 (1.0 to 4.0)
• The guideline has been piloted among end users 1.1 (1.0 to 1.7)
Overall standardized score, %) 50.9 (8.3 to 75.0)
3 (Rigour of development) • Systematic methods were used to search for evidence 2.6 (1.0 to 4.0)
• The criteria for selecting the evidence are clearly described 2.8 (1.0 to 4.0)
• The methods used for formulating the recommendations are clearly described 3.0 (1.0 to 4.0)
• The health benefits, side effects, and risks have been considered in formulating the
recommendations
3.1 (1.7 to 4.0)
• There is an explicit link between the recommendations and the supporting evidence 3.1 (1.3 to 4.0)
• The guideline has been externally reviewed by experts before its publication 2.3 (1.0 to 4.0)
• A procedure for updating the guideline is provided 1.7 (1.0 to 4.0)
Overall standardized score, % 55.5 (7.9 to 96.8)
4 (Clarity and
presentation)
• The recommendations are specific and unambiguous 3.4 (2.3 to 4.0)
• The different options for management of the condition are clearly presented 3.4 (2.3 to 4.0)
• Key recommendations are easily identifiable 3.7 (2.7 to 4.0)
• The guideline is supported with tools for application 3.0 (1.0 to 4.0)
Overall standardized score, % 79.7 (55.6 to 100.0)
5 (Applicability) • The potential organizational barriers in applying the recommendations have been discussed 2.2 (1.0 to 4.0)
• The potential cost implications of applying the recommendations have been considered 2.4 (1.0 to 4.0)
• The guideline presents key review criteria for monitoring and/or audit purposes 1.7 (1.0 to 3.7)
• Overall standardized score, % 37.0 (0.0 to 88.9)
6 (Editorial independence) • The guideline is editorially independent from the funding body 2.2 (1.0 to 4.0)
• Conflicts of interest of guideline development members have been recorded 2.6 (1.0 to 4.0)
Overall standardized score, % 47.4 (0.0 to 100.0)
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six the AGREE domains, however, a significant differ-
ence was not detected, probably due to the small sample
size.
Conclusions
The high number of guidelines with low methodological
quality in the literature on genetic testing for hereditary
breast cancer prompted us to evaluate their methodologi-
cal quality scientifically. We also provided an insight on
important factors that have been missed out of some
guidelines, and which, in our opinion, should be consid-
ered. The whole objective of using the AGREE instru-
ment is to provide a common ground on rigor and
transparency of guideline development, and to suggest
how to improve on the existing guidelines [4]. In this
sense, the most self-explanatory example is that of con-
flicts of interest; the AGREE instrument recommends
that guidelines always report explicitly whether conflicts
exist or not. The absence of an explicit statement does
not necessarily mean that a conflict of interest exists, but
rather that providing such a statement was not a stan-
dard procedure in the development of the guidelines. We
would recommend that all future guidelines should
always state explicitly that conflicts of interest do or do
not exist.
It is noteworthy that the results reported here are very
similar to those reported for guidelines focusing on genetic
forms of colorectal cancer [11]. Although this study and
the previous study do not cover the whole subject of
genetic-testing guidelines, they certainly corroborate each
other in the notion that there is much to be achieved and
improved in terms of methodology and quality where
genetic tests are concerned.
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